Morgens Waterfall Vintiadis & Co’s Editas Medicine EDIT Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-15,000	Closed	-$444K	–	39
2019 Q4	$444K	Hold	15,000	–	–	0.3%	48
2019 Q3	$341K	Hold	15,000	–	–	0.26%	50
2019 Q2	$371K	Hold	15,000	–	–	0.26%	50
2019 Q1	$367K	Hold	15,000	–	–	0.26%	54
2018 Q4	$341K	Hold	15,000	–	–	0.3%	55
2018 Q3	$477K	Sell	15,000 -15,000	-50%	-$485K	0.31%	54
2018 Q2	$1.07M	Hold	30,000	–	–	0.76%	35
2018 Q1	$995K	Buy	30,000 +10,000	+50%	+$356K	0.76%	37
2017 Q4	$615K	Hold	20,000	–	–	0.48%	37
2017 Q3	$480K	Buy	+20,000	New	+$381K	0.4%	43

Other funds holding EDIT

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's EDIT Position: Q1 2020 in Review

Morgens Waterfall Vintiadis & Co sold out of Editas Medicine (EDIT) in Q1 2020, closing a stake of 15,000 shares — an estimated $444K sold.

Morgens Waterfall Vintiadis & Co first reported a position in EDIT in Q3 2017 and held it in 10 quarters. The position peaked at $1.07M in Q2 2018. 199 funds tracked by Wall St. Rank hold EDIT as of Q1 2020.

Morgens Waterfall Vintiadis & Co reported no remaining Editas Medicine position as of Q1 2020 after selling out during the quarter.
Morgens Waterfall Vintiadis & Co sold 15,000 Editas Medicine shares in Q1 2020, an estimated $444K.
Morgens Waterfall Vintiadis & Co first reported a position in Editas Medicine in Q3 2017 and held it in 10 quarters.
Morgens Waterfall Vintiadis & Co's Editas Medicine position peaked at $1.07M in Q2 2018.
199 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2020.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q1 2020, filed 15 May 2020.